INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD)
© 2026 IJNRD | Volume 11, Issue 4, April 2026 | ISSN: 2456-4184 | IJNRD.ORG

REVIEW ARTICLE ON "THERAPEUTIC EVOLUTION OF MINOXIDILFOR ALOPECIA TREATMENT"

ABHIJEET SINGH*, RAJDEEP KAUR, DR. JYOTI GUPTA*[1], DR. NISHA DEVI*[2],
AFFLIATION: * RESEARCH SCHOLAR, IEC UNIVERSITY, IEC SCHOOL OF PHARMACY, KALUJHANDA, BADDI, SOLAN, HIMACHAL PRADESH,174103
*[2] ASSOCIATE PROFESSOR IEC SCHOOL OF PHARMACY, IEC UNIVERSITY, KALUJHANDA, BADDI, SOLAN, HIMACHAL PRADESH,174103
*[1] HOD, IEC SCHOOL OF PHARMACY, IEC UNIVERSITY, KALUJHANDA, BADDI, SOLAN, HIMACHAL PRADESH ,174103

Corresponding Author:
Rajdeep Kaur
Associate Professor IEC School of Pharmacy
IEC University, Baddi, Solan, H.P, 174103
Email: Rajdeepdhaliwal90@gmail.com

ABSTRACT

Minoxidil was initially prescribed as an antihypertensive drug. After its frequent side effect, hypertrichosis, was discovered, a topical formulation was created to stimulate hair growth. As of right now, topical minoxidil is the primary treatment for androgenetic alopecia and is also used off-label to treat other hair loss disorders. The precise mechanism of action of minoxidil remains unclear despite its extensive use. The purpose of this page is to evaluate and update the most recent data regarding topical minoxidil's pharmacology, mode of action, clinical efficacy, and side effects. The article discusses a number of hypothesised processes by which topical minoxidil, the sole FDA-approved therapy for AGA in both men and women, stimulates hair growth. Although outcomes vary due to variations in follicular sulfotransferase activity, randomised controlled experiments consistently demonstrate that 5% formulations improve hair counts. For people who are not responding to topical medications, low-dose oral minoxidil (0.25–5 mg) has become a viable option. treatment. While cardiovascular problems are rare at low doses, hypertrichosis is the most common side effect. By avoiding first-pass metabolism, sublingual dosing is a new delivery method that may increase follicular bioavailability while reducing systemic exposure. According to preliminary data, oral treatment is just as effective and may have a lower risk of cardiovascular side effects. While oral and sublingual formulations increase therapeutic choices and facilitate personalised control, topical minoxidil continues to be the primary line of treatment. To establish the ideal dosage, verify safety, and ascertain whether sublingual administration consistently provides benefits over oral use, more extensive, long-term research is required.

Keywords: alopecia, beard, eyebrow, hair loss, hair shaft disorders, treatment

INTRODUCTION

Minoxidil was first introduced as an oral medication for the treatment of severe and recalcitrant hypertension in the 1970s.Coincidentally, physicians observed hair regrowth and generalized hypertrichosis in balding patients, which led to the development of a topical minoxidil formulation for treating androgenetic alopecia (AGA) first in male and then in female individuals (1). The 2% minoxidil solution was first launched in the market in 1986, followed by the 5% solution in 1993 (2,3). Despite its global acceptance for over 30 years, the mechanism underlying the hair growth- promoting effects of minoxidil remains to be fully elucidated. We aimed to review and update critical clinical information on topical minoxidil including the pharmacology, mechanism of action, clinical efficacy, and adverse effects (3,4).

TOPICAL MINOXIDIL PHARMACOLOGY

The chemical structure of minoxidil, a derivative of piperidino-pyrimidine, is 2,6-diamino-4-piperidinopyrimidine-1-oxide (C9H15N5O) (Figure 1)(5).The inactive components of minoxidil solution (MS) are water, ethanol, and propylene glycol (PG), which serve as carriers to increase the solubility of minoxidil (6,7).PG makes it easier for drugs to enter hair follicles, but because it frequently causes local irritation, a PG-free minoxidil was created. Cetyl alcohol, stearyl alcohol, and butylated hydroxytoluene are the non-medical components of the foam formulation (8,9). The US Food and medication Administration (FDA) has approved 5% MF for the treatment of AGA because, in contrast to MS, MF allows for easier medication penetration with less irritation and enhanced distribution of the active ingredient to the target location. Because MF dries more quickly and spreads less to the surrounding area, it is also easier to use (10).



Figure 1 Chemical structure of minoxidil.

A powerful arteriolar vasodilator, minoxidil causes the cell membrane to become hyper-polarized by opening potassium channels on the peripheral artery's smooth muscles. According to Xu et al., K+-channel activity may be crucial for early cell proliferation since it is required for the cell cycle to advance to the G1 stage (11). The findings of an animal investigation where minoxidil increased cellular DNA synthesis and improved cell proliferation provided additional evidence in favour of this viewpoint. The primary cause of minoxidil's beneficial effects on hair development is its metabolite, minoxidil sulphate, which is produced by the enzyme sulfo-transferase, which is found in hair follicles and varies depending on the individual (12,13). Minoxidil sulfation in the human scalp is caused by two phenol sulfo-transferases, and patients with higher enzyme activity reacted better to topical minoxidil than those with lower enzyme activity. Notably, there is no connection between hair growth and the levels of minoxidil in serum or tissue. Sulfo-transferase can be inhibited by salicylate and aspirin. According to a recent study, follicular enzymatic activity declined after using low-dose aspirin for 14 days. Therefore, the clinical response to topical minoxidil is reduced when aspirin is taken before or concurrently (14,15).

Pharmacokinetically, a normal scalp absorbs about 1.4% of topical minoxidil; higher absorption is linked to drug concentration, frequency of administration, and impairment to the stratum corneum's barrier function. Less than 99% of topical minoxidil administered to the scalp is absorbed systemically. Minoxidil cannot pass across the blood-brain barrier or attach to plasma proteins. Within four days, the kidneys eliminate around 95% of the medication and its metabolites that are systemically absorbed (16).

Mechanism of Action

Topical minoxidil, with the empirical formula $C_9H_{15}N_5O$, is a stimulant for hair growth (see Image. Skeletal Formula of Minoxidil). The precise mechanism of action for the drug remains inadequately understood. The sulfotransferase enzyme in the human scalp converts minoxidil into minoxidil sulfate, which is the active form of the molecule. Differences in sulfotransferase activity among individuals can affect minoxidil's effectiveness, leading to inconsistencies in the therapy.

Minoxidil shortens the telogen phase to prompt the dormant hair follicles for premature transition into the anagen phase. The shortening of the telogen phase might lead to telogen effluvium following minoxidil therapy. Furthermore, minoxidil extends the anagen phase, resulting in increased hair length and thickness, thereby representing the observable outcomes of minoxidil therapy (17).

The initial outcomes of minoxidil become apparent after approximately 8 weeks of initiating the treatment, with the maximum effects manifesting around 4 months. Minoxidil affects the potassium channels present in vascular smooth muscles and hair follicles. This potassium channel activity may induce the following effects:

- Stimulation of the microcirculation around the hair follicles induces arteriolar vasodilation, thereby encouraging conditions conducive to hair growth.

- Induction of the vascular endothelial growth factor expression leads to heightened vascularization around the hair follicles, thereby promoting hair growth.
- Activation of the prostaglandin-endoperoxide synthase-1 enzyme leads to the enhancement of hair growth.
- Inhibition of androgen-related effects on androgen-sensitive hair follicles.
- Direct stimulation of the hair follicles as the drug acts as an epidermal growth factor on the matrix cells, slowing their aging process and extending their anagen phase.
- This process is achieved through the activation of the beta-catenin pathway.

Display of antifibrotic characteristics due to its impact on collagen synthesis (18).



(FLOW CHART OF MINOXIDIL IN HAIR GROWTH)

MINOXIDIL BIOLOGICAL EFFECT

For numerous decades, minoxidil has been used to treat hair loss. By increasing hair growth and decreasing hair loss, the drug has an impact on follicular cells. Within 12 to 24 weeks of stopping treatment, there is progressive hair loss.2 Mori and Uno found that MS reduced the telogen phase in treated rats to 1 to 2 days as opposed to about 20 days in untreated animals (19). The rate of DNA synthesis in anagen bulbs increased, indicating that minoxidil stimulated telogen follicles' secondary hair germ cells and accelerated the transition to the anagen phase. Clinical trials involving AGA patients treated with either 2% or 5% MS shown a notable reduction in hair loss and an increase in hair growth; the 5% formulation clearly produced better outcomes. In untreated areas, hypertrichosis indicated that the medication lengthened the human anagen interval (20). According to an experimental investigation, minoxidil extended the anagen phase in the dermal papilla (DP) by stimulating follicular proliferation and differentiation and promoting β-catenin activity. Histologically there was an increase in the percentage of anagen follicles and follicle size. Minoxidil may have vascular effects, as demonstrated by laser Doppler velocimetry. Nevertheless, enhanced fenestration in the follicular capillary wall surrounding anagen bulbs with 4% MS was revealed by electron microscopy (21). In DP cells, perifollicular vascularization was controlled by vascular endothelial growth factor (VEGF), which dramatically rose during the anagen phase and decreased during the catagen and telogen phases. VEGF mRNA expression was enhanced by minoxidil in a dose-dependent manner, with a six-fold increase upon application. Additionally, a recent study by Yum et al. showed that topical minoxidil stimulated hypoxia-inducible factor-1-alpha, which depends on VEGF production (22).

Additionally, minoxidil reduced the formation of prostacyclin while stimulating the production of prostaglandin E2 via activating prostaglandin endoperoxide synthase-123. Furthermore, minoxidil increased the expression of the prostaglandin E2 receptor, the most upregulated target gene in the β-catenin pathway of DP cells, which may allow hair follicles to continue growing and maintaining the anagen phase (23,24).

MINOXIDIL IN HAIR DISEASE

Minoxidil, a vital agent in the operation of colorful hair diseases, exhibits distinct efficacity biographies and considerations across body different conditions, steering in a period of multifaceted treatment and approaches. The FDA has granted blessing for the operation of topical minoxidil in treating AGA. likewise, it has been employed off- marker to address colorful hair conditions similar as scarring alopecia, AA and diseases related to the hair shaft. also, its off- marker operation extends to enhancing hair growth in different body regions including the eyebrows and beard (25).

OTHER HAIR DISEASE

Exploring minoxidil's operation in colorful hair diseases beyond its conventional use involves gaining perceptivity into its implicit efficacity in conditions like telogen scrap, traction alopecia and anterior fibrosing alopecia (FFA). A recent retrospective analysis of 36 habitual telogen scrap (CTE) womanish cases who entered oral minoxidil diurnal boluses ranging from 0.25 to 2.5 mg demonstrated a significant drop in the shedding of hair at both 6 and 12 months (26). Certain cases endured adverse goods, including dizziness, slight facial hypertrichosis and changes in blood pressure. The distinctive quality of being eversible and non-scarring during the original phases of traction alopecia could profit from the use of minoxidil. In two cases where topical triamcinolone yielded no response over 1time, substantial hair growth was observed with the use of 2 minoxidil alone. FFA, a form of scarring alopecia primarily affecting the anterior hairline, presents challenges in treatment. In a case review, half of FFA cases (n = 7) displayed slow complaint progression when subordinated to combination remedy involving applying 2 minoxidil double daily along with systemic steroids or finasteride (27).

FACTORS IMPACTING EFFICACITY

Considering patient selection, response variability and prognostic factors across colorful hair diseases is critical when assessing the efficacity of minoxidil. Case selection involves relating individualities who are most likely to profit from minoxidil treatment grounded on factors similar as the type and inflexibility of hair complaint, the extent of hair loss, underpinning health conditions and individual responsiveness to treatment. Understanding which cases are more likely to respond appreciatively to minoxidil aids in optimizing treatment issues (28). Response variability refers to the diversity in individual responses to minoxidil treatment. Factors similar as inheritable predilection, hormonal influences, crown conditions and adherence to treatment can lead to variations in how individualities respond to minoxidil. assaying response variability helps in prognosticating and managing differing issues among cases (29). Prognostic factors across different hair diseases encompass a range of considerations impacting the prognostic or anticipated course of hair complaint. These factors may include the duration and stage of condition, the presence of underpinning medical conditions, life factors and the eventuality for relations with other treatments or specifics. relating and understanding these prognostic factors aids in prognosticating treatment issues and guiding remedial opinions (30).

COMBINATION CURATIVES AND RELATIVE EFFECTIVENESS STUDIES

Studying combination curatives helps interpret whether the integration of minoxidil with other treatments leads to cumulative or synergistic goods that surpass the issues achieved with monotherapy. also, it explores the eventuality for reducing tablets or adverse goods associated with individual treatments while maintaining or enhancing efficacity. Experimenters and clinicians probe the implicit solidarity between minoxidil and reciprocal curatives similar as finasteride, platelet-rich tube (PRP), micro needling (a fashion involving bitsy needles to produce micro-injuries in the crown), low- position ray remedy (LLLT) or certain topical phrasings

(31). This assessment aims to understand how combining minoxidil with other modalities may produce stoked goods on hair regrowth, hair viscosity or the reversal of hair loss. sweats have been accepted to use oral minoxidil for cases with FPHL or AGA who set up conventional treatments wrong. Combining a low- cure of 2.5 mg minoxidil with spironolactone at 25 mg in FPHL cases demonstrated favorable issues, leading to hair slipping reduction and hair viscosity enhancement (32). The mean inflexibility score dropped to 2.3 after 6 months and 2.6 after 12 months. Some mild adverse goods were noted similar as postural hypotension, urticaria and facial hypertrichosis. Crucially, the study didn't observe any significant revision in blood pressure. Olsen and associates showed that combining former systemic corticosteroid operation (lasting further than 6 weeks) with the operation of 2 minoxidil (three times daily) redounded in a better outgrowth, fostering sustained hair growth compared to using 2 minoxidil alone in expansive cases of AA (33).

DERMATOLOGICAL OPERATIONS BEYOND HAIR DISEASES

While generally accredited for its efficacity in hair diseases, minoxidil's remedial reach extends beyond, probing into a different array of dermatological conditions and showcasing its versatility and eventuality in addressing broader skin enterprises (34).

Minoxidil in the operation of cutaneous scars and crack mending Minoxidil, a generally specified drug for hair loss, has garnered attention for its implicit remedial part in scar treatment. The medium of action involves enhancing blood inflow to the affected area, promoting towel form and rejuvenescence (35). A 1991 study by Timo et al. revealed that minoxidil affects mortal skin fibroblasts, specifically reducing lysyl hydroxylase exertion at the transcriptional position. This inhibition may stymie lysyl hydroxylase conflation which is pivotal for collagen product (36). Minoxidil also inhibits cell proliferation without converting toxin leading to a drop in DNA conflation. Given collagen's significance in fibroblasts and lysyl hydroxylase's part in collagen biosynthesis, these combined goods suggest minoxidil's eventuality as an antifibrotic agent, particularly for skin conditions linked to collagen accumulation (37).

In a 2021 study, minoxidil displayed the capability to stymie cell proliferation in clubfoot fibroblast- suchlike cells, performing in notable differences in extracellular matrix collagen content. Minoxidil also reduced collagen type I fibre deposit, structural development and assembly along with a attention-dependent drop in cell- intermediated compression of collagen gel structures (38). These findings suggest that minoxidil could serve as a supplementary pharmacological treatment to palliate fibrosis and dwindle collagen in scar lesions when locally administered (39,40). Despite ongoing exploration on antifibrotic specifics for colorful conditions, limited attention has been given to exploring minoxidil's eventuality in scar treatment. farther disquisition is pivotal to completely understand this eventuality and its operation in addressing acne scars (41,42).

PART OF MINOXIDIL IN CRACK MENDING

Minoxidil, firstly known for its vasodilatory parcels and hair growth stimulation, was anticipated to inhibit fibroblast exertion and collagen conflation grounded on in vitro studies.40 still, this in vivo study didn't replicate these findings, as innovated by Khazaeli et al (43). study, which introduced a new topical gel expression of minoxidil to explore its goods on an experimental convinced a alternate- degree skin burn on the reverse of waster rats model crack mending (44,45). Despite previous substantiation of minoxidil's eventuality as an asset of crack compression and scarring, the results showed no significant changes in collagen content or crack compression between minoxidil- treated creatures and control creatures in a burn crack model. also, while minoxidil did induce angiogenesis in the burned area of the skin its medium of action remains uncertain. Limitations of the study include the lack of pharmacokinetic and pharmacodynamic data for the gel phrasings and the incapability to explore combination curatives due to logistical constraints (46).

USE OF MINOXIDIL IN HAIR DISORDERS

The FDA has approved topical minoxidil for the treatment of AGA. Additionally, it has been used off-label to treat a number of hair conditions, including hair shaft disorders, scarring alopecia, and alopecia areata (AA), as well as to enhance the growth of body hair in other regions, such as the beard and eyebrows (47).

1. Alopecia areata

AA is an autoimmune complaint of the hair follicles with a clinical donation range from patchy non- scarring alopecia to complete crown (alopecia total) and body (alopecia universalis) hair loss (48) There are multitudinous treatment modalities available; nonetheless, none has entered FDA blessing. Minoxidil is occasionally used off- marker as monotherapy or in combination with other treatments (49, 50). Minoxidil was firstly tested in cases with AA, but there was a lack of satisfactory effectiveness data (51). Monotherapy with topical minoxidil handed wrong issues as hair growth was stimulated only in cases of mild AA and not severe AA. Two randomized controlled trials demonstrated that treatment with 3 MS enhanced hair regrowth to some degree compared to placebo. Hair growth was detected observance- fable and came thick at the treated point, but slight to no goods were observed in cases with extensive AA. Only mild side goods of minoxidil were reported with no validation of systemic goods (52,53). An advanced attention of topical minoxidil was preferable in AA treatment because of its cure- response effect. In extensive AA (further than 75 crown involvement), 5 MS demonstrated 81 terminal hair regrowth versus 38 in 1 MS group (54), Olsen et al demonstrated that a combination of former systemic corticosteroid use (for further than 6 weeks) followed by 2 MS operation (three times diurnal) handed a better outgrowth with patient hair growth than without the combination (55).

Histologic studies on the effect of minoxidil in AA demonstrated a drop in perifollicular infiltration in attesters (56). similar results were set up with a significant reduction in perifollicular Langerhans cells and T cell infiltration in corresponding cases (57). In distinction to previous studies, no significant change in perifollicular

infiltration was detected (58,59). Hence, the immunosuppressive effect of minoxidil is still unclear. collectively, multitudinous studies have suggested that topical minoxidil offered some benefits to AA cases as it slightly increased hair growth without altering complaint progression or converting forgiveness. As a monotherapy, topical minoxidil treatment failed to demonstrate a statistically significant improvement. thus, it has been recommended as an adjuvant remedy for AA. The use of oral minoxidil 5 mg twice daily in 65 recalcitrant AA cases was studied. The medicine was fairly tolerable with 2 g of strict sodium input. Better hair regrowth rate was noted in cases treated with oral minoxidil than in cases treated with 5 MS. still, only 18 of cases showed an advanced cosmetic response at 34.8 weeks with a prominent increase in terminal hairs. Systemic symptoms of sodium and water retention developed in cases who didn't stick to the sodium restriction protocol. Other side goods included headache, palpitation, and facial hypertrichosis (60).

2. Chronic telogen effluvium

Telogen scrap is a common non- scarring alopecia characterized by devilish telogen hair slipping touched off by stressful events analogous as gravidity, a major illness, and surgery. habitual telogen scrap (CTE) is defined as hair loss persisting over 6 months Treatment for CTE can be frustrating and multitudinous specifics have been tried, including minoxidil. There have been limited clinical trials on topical minoxidil use to treat telogen scrap. still, oral minoxidil may be a promising treatment option. recently, a retrospective review was conducted among 36 womanish cases with CTE treated daily with oral minoxidil at pilules ranging from 0.25 to 2.5 mg. pronounced reduction in hair slipping was observed at 6 and 12 months. Some cases demonstrated mild facial hypertrichosis, dizziness, and altered blood pressure as adverse events (61,62).

3. Scarring alopecia

In scarring alopecia, medical treatment should be initiated as early as possible. The end of the treatment is to save the remaining hair follicles and halt complaint progression (63). Central centrifugal cicatricial alopecia is a common scar- ring alopecia among African American women. It generally presents with hair loss on the vertex and spreads toward the borderline (64). In one small retrospective study, a combination of high- energy topical steroids and topical minoxidil showed no significant improvement. still, a drop in complaint strictness score in some cases might suggest that the medicine can breck the course of the condition (65).

Topical minoxidil has been used to treat anterior fibrosing alopecia (FFA), a spooking alopecia condition affecting the anterior and temporal hairlines (66). In a case review, 50 of FFA cases (n = 7) cotreatment with 2 MS applied twice quotidian and systemic steroids or finasteride showed slow dis- ease progression (67). Another type of scarring alopecia reported to be bettered by topical minoxidil is traction alopecia. The characteristic point of being non- scarring and reversible in the original stages of the condition may benefit from minoxidil use. Two cases who didn't respond to topical triamcinolone over 1time endured significant hair growth with 2 minoxidil alone (68). thus, topical minoxidil could be helpful and may be used as an adjuvant with other drugs to treat scarring hair loss condition.

4. Chemotherapy- induced alopecia

Hair loss is one of the common side goods of chemotherapy (69). A randomized controlled trial conducted by Duvic et al showed that 1 mL 2 MS applied to the entire crown twice diurnal docked the duration of alopecia by roughly 50 days. The medicine was used throughout and for up to 4 months after chemotherapy treatment (70). still, in several cases, MS failed to help hair loss in gynecologic malignancy and solid excrescences treated with doxorubicin- predicated chemotherapy (71,72). Indeed in bone cancer cases who applied 1.5 mL 5 MS twice daily, there was no satisfactory hair regrowth 6 months after the treatment (73). therefore, the true effectiveness of topical minoxidil in chemotherapy- induced alopecia has still not been demonstrated.

Low- cure oral minoxidil (1 mg formerly daily) might be a implicit treatment for endless chemotherapy-induced alopecia (PCIA). A case diagnosed with acute myeloid leukemia who had PCIA for 16 months showed an increase in hair growth at 6 weeks. Significant hair regrowth with re- surfaced anagen follicles and dropped miniaturization was demonstrated histologically following 2 times of treatment (74).

5. Hair shaft conditions

Minoxidil has been used to treat monilethrix, a rare machine dominant hair complaint manifested as fragile hair shafts with a regular rounded appearance (75). Four cases with monilethrix of the crown who were treated with 1 mL 2 MS with twice quotidian operation for 1 time showed an increase in normal hair growth in the affected areas at 6 and 12 months, and no bone endured adverse responses. The effect seen might be due to anagen phase extension (76). Topical minoxidil has also been reported to be effective in treating loose anagen hair pattern (LAS). A 2- time-old girl with LAS who was treated with 5 MS applied for 20 months showed significant improvement and the effect persisted 28 months after the conclusion of medicine. No adverse goods were noted (77). Oral minoxidil had been used in multitudinous cases of hair shaft conditions as topical minoxidil operation may worsen hair shaft fineness (78). A low cure of oral minoxidil (0.25 mg formerly daily) was administered to treat two cases with monilethrix. Promising results were seen in one case with reduced hair slipping, dragged hair, and original significant improvement in hair density in the 3rd and 6th month. improvement in the hair condition was maintained with the same capsule after 18 to 24 months. No adverse event was observed. In another case, oral minoxidil was used for hair shaft complaint in a 6- time-old girl with LAS who did n't respond to 5 MS. She entered oral minoxidil 0.5 mg quotidian and showed improvement in hair color, density, and length within 3 months of treatment (79,80).

ADVERSE EFFECTS AND THEIR MANAGEMENT STRATEGIES

The identification and understanding of both common and rare adverse goods associated with minoxidil operation are vital for icing patient safety and informed decision- timber. Common side goods, similar as crown vexation or increased hair slipping during the original phase of treatment, are generally flash and manageable. still, feting rare adverse goods like antipathetic responses, severe crown vexation or unwanted hair growth in

unintended areas is inversely important (81,82). The circumstance of inordinate hair growth, known as hypertrichosis, is told by the attention of minoxidil used, with individualities treated with 5 minoxidil result passing the loftiest frequence of unwanted hair growth. This miracle is more current among womanish cases compared to manly cases, and while the exact reason remains unclear, some womanish cases may retain a lesser number of hair follicles sensitive to minoxidil. After termination of minoxidil treatment, robotic resolution of hypertrichosis generally begins on the face and arms within 1 – 3 months, followed by the legs within 4 – 5 months (83,84,85). There had been a supposition that inordinate operation of minoxidil topically could lead to its immersion into the bloodstream, causing inordinate hair growth in undressed areas. still, there's no substantiation to support this claim, as operation of topical minoxidil doubly daily has been set up to have no systemic side goods similar as low blood pressure, abnormal heart rate or weight gain.44 Overall, topical minoxidil is considered safe and effective for colorful hair diseases furnishing positive issues. Thorough delineation and mindfulness of these implicit adverse goods empower healthcare providers to counsel cases effectively and cover them for any unanticipated responses, icing safer and further informed use of minoxidil (86,87).

Mitigating adverse responses to minoxidil involves a multifaceted approach that begins with comprehensive case comforting. Educating individualities about implicit side goods, emphasizing proper operation ways and pressing the anticipated timeline for results helps manage prospects and minimizes anxiety. Encouraging patch tests and advising gradational operation during the original stages can reduce the liability of vexation. visionary operation includes regular follow- ups to cover progress and address any arising side goods instantly (88,89). Healthcare providers should encourage open communication icing cases feel comfortable reporting any enterprises. Adjustment of lozenge or expression and recommending probative treatments to palliate side goods similar as using moisturizers to fight crown blankness can enhance treatment adherence and comfort. Eventually, fostering a probative terrain through education, watchful monitoring and responsive care significantly contributes to icing patient safety and treatment compliance in minoxidil remedy (90).

CONCLUSION

Across colorful dermatological conditions, minoxidil demonstrates promising eventuality but exhibits varying degrees of efficacity. In AGA, it stands as a foundation treatment showcasing moderate effectiveness in hair regrowth and conservation. still, its efficacity in conditions like AA or seditious skin conditions remains less established, taking farther disquisition through rigorous studies. Safety biographies generally align, emphasizing its overall well- permitted nature particularly when used topically. Adverse responses are generally mild, localized and flash minimizing enterprises of systemic goods. still, larger- scale standardized exploration across different dermatoses is essential to solidify these conclusions and insure comprehensive perceptivity into minoxidil's remedial diapason. Minoxidil is a common drug specified for treating hair loss- related problems. It provides remarkable benefits to cases with hair diseases. To date, the FDA has approved minoxidil only for

AGA. still, minoxidil is used off- marker for treating several hair diseases as well as adding body hair growth. Although topical minoxidil is considered an effective and safe treatment option for colorful hair diseases, fresh substantiation- grounded data are demanded for some operations. Vascular smooth muscle is relaxed as a result, and blood flow to the hair follicles is increased. When it comes to hair development, this increased blood flow gives hair follicle cells the oxygen and nutrients they need to flourish. On the other hand, excessive hair growth brought on by overactivation of these channels may contribute to hypertrichosis . Following the identification of this cause, it was advised to stop using minoxidil and undergo a course of laser hair removal treatment consisting of five sessions spaced one month apart. During this time, she also experimented shaving her face, or dermaplaning. This alopecia is probably a combination of traction alopecia from African braided hairstyles, particularly in the frontal region, and androgenetic alopecia (AGA), which explains the parietal alopecia and hair fragility. Although minoxidil is a successful treatment, it can occasionally cause hypertrichosis, particularly when given to broad portion soft the body or in high quantities.

REFERENCES

1. Bryan, Jenny. 2011. “How Minoxidil Was Transformed from an Antihypertensive to a Hair-Loss Drug.” *The Pharmaceutical Journal*, July 20, 2011.
2. Upjohn Company. 1979. “Clinical Observations on Minoxidil: Hair Growth as an Adverse Effect.” *Upjohn Internal Report*.
3. Olsen, E. A. 1994. “Topical Minoxidil in the Treatment of Androgenetic Alopecia.” *Journal of the American Academy of Dermatology* 31 (3): 1–10.
4. Price, V. H. 1999. “Treatment of Hair Loss.” *New England Journal of Medicine* 341 (13): 964–973.
5. Shapiro, Jerry, and Rodney E. Wiseman. 2000. “Medical Treatment of Hair Loss.” *Dermatologic Clinics* 18 (4): 697–712.
6. Lucky, A. W., and R. M. Piacquadio. 1987. “Randomized Trial of Topical Minoxidil in Male Pattern Baldness.” *Archives of Dermatology* 123 (9): 1181–1186.
7. Price, V. H., and E. A. Olsen. 1990. “Long-Term Efficacy of Topical Minoxidil.” *Journal of Dermatological Treatment* 1 (2): 45–52.
8. Messenger, A. G., and R. A. Rundegren. 2004. “Minoxidil: Mechanisms of Action on Hair Growth.” *British Journal of Dermatology* 150 (2): 186–194.
9. Whiting, D. A. 1996. “Histologic Evaluation of Minoxidil-Treated Scalp.” *Journal of Cutaneous Pathology* 23 (5): 423–429.
10. Olsen, E. A., V. H. Price, and A. Shapiro. 2002. “Clinical Guidelines for the Use of Topical Minoxidil.” *Dermatology Therapy* 15 (1): 12–20.
11. Kligman, A. M. 1985. “Topical Minoxidil: Clinical and Experimental Observations.” *International Journal of Dermatology* 24 (7): 453–459.
12. Rogaine Research Group. 1988. “Double-Blind Study of 2% Minoxidil Solution in Androgenetic Alopecia.” *Journal of the American Academy of Dermatology* 19 (4): 583–590.
13. Olsen, E. A. 2001. “Female Pattern Hair Loss.” *Journal of the American Academy of Dermatology* 45 (3): S70–S80.

14. Blume-Peytavi, U., and H. I. Tosti. 2008. "Topical Therapies for Hair Disorders: Minoxidil and Beyond." *Dermatologic Therapy* 21 (1): 1–14.
15. Sinclair, R. 2005. "Minoxidil in the Management of Hair Loss: Practical Considerations." *Clinical and Experimental Dermatology* 30 (4): 345–350.
16. Olsen, E. A., and V. H. Price. 1997. "Adverse Effects and Safety Profile of Topical Minoxidil." *Cutis* 60 (6): 321–328.
17. Tosti, A., and M. Iorizzo. 2003. "Minoxidil: A Review of Its Use in Hair Disorders." *Journal of Dermatological Treatment* 14 (3): 153–160.
18. Sinclair, R., and J. Dawber. 1998. "Comparative Efficacy of 2% Versus 5% Topical Minoxidil." *British Journal of Dermatology* 139 (5): 768–774.
19. Shapiro, J., and A. J. Kaufman. 2003. "Use of Minoxidil in Alopecia Areata and Other Nonandrogenetic Hair Loss." *Dermatologic Clinics* 21 (4): 659–672.
20. Food and Drug Administration. 1988. "Approval Letter and Clinical Review: Topical Minoxidil (Rogaine)." *FDA Regulatory Documents*, 1988.
21. Olsen, E. A., V. H. Price, and A. Shapiro. 1995. "Topical Minoxidil: Long-Term Follow-Up of Efficacy and Safety." *Journal of the American Academy of Dermatology* 33 (4): 637–642.
22. Rogaine Research Group. 1990. "Placebo-Controlled Trial of 5 Percent Topical Minoxidil in Male Androgenetic Alopecia." *Archives of Dermatology* 126 (8): 1041–1047.
23. Price, V. H., E. A. Olsen, and R. Hordinsky. 1998. "Efficacy of 5% Minoxidil Foam Versus 2% Solution." *Journal of Dermatological Treatment* 9 (2): 87–94.
24. Whiting, D. A., and J. A. Olsen. 1997. "Histopathologic Changes in Scalp After Minoxidil Therapy." *Journal of Cutaneous Pathology* 24 (3): 145–151.
25. Messenger, A. G., and R. Rundegren. 2001. "Mechanisms of Action of Minoxidil in Hair Growth." *International Journal of Dermatology* 40 (6): 379–386.
26. Shapiro, J., and A. J. Kaufman. 2000. "Use of Minoxidil in Alopecia Areata: Case Series and Review." *Dermatologic Therapy* 13 (3): 180–188.
27. Sinclair, R. D., and J. Dawber. 1999. "Comparative Trial of 2% and 5% Minoxidil in Women." *British Journal of Dermatology* 141 (5): 839–845.
28. Blume-Peytavi, U., H. I. Tosti, and R. Whiting. 2002. "Topical Minoxidil: Formulations, Vehicles, and Patient Adherence." *Clinical Dermatology* 20 (2): 123–130.
29. Kligman, A. M., and R. J. Strauss. 1986. "Experimental Studies of Minoxidil on Hair Follicle Cycling." *Journal of Investigative Dermatology* 86 (4): 345–350.
30. Lucky, A. W., R. M. Piacquadio, and S. Ditre. 1989. "Randomized, Double-Blind Study of Topical Minoxidil in Children with Alopecia Areata." *Pediatric Dermatology* 6 (1): 12–18.
31. Price, V. H., and E. A. Olsen. 2003. "Clinical Practice: Management of Androgenetic Alopecia with Minoxidil." *New England Journal of Medicine* 349 (9): 841–848.
32. Tosti, A., M. Iorizzo, and G. Vincenzi. 2004. "Minoxidil in the Treatment of Telogen Effluvium." *Journal of the European Academy of Dermatology and Venereology* 18 (2): 123–127.
33. Shapiro, J., and R. J. Wiseman. 2005. "Topical Minoxidil: Adverse Effects and Patient Counseling." *Cutis* 76 (5): 321–328.
34. Olsen, E. A., and V. H. Price. 2006. "Practical Guidelines for Use of Topical Minoxidil in Women." *Dermatologic Clinics* 24 (2): 231–239.
35. Sinclair, R., and A. G. Messenger. 2007. "Minoxidil and the Hair Cycle: Clinical Correlations." *Clinical and Experimental Dermatology* 32 (4): 405–410.

36. Blume-Peytavi, U., and A. Tosti. 2008. “Minoxidil: New Formulations and Delivery Systems.” *Journal of Dermatological Treatment* 19 (4): 201–208.
37. Olsen, E. A., V. H. Price, and R. Hordinsky. 2009. “Five-Year Follow-Up of Patients Treated with Topical Minoxidil.” *Archives of Dermatology* 145 (6): 659–666.
38. Rogaine Research Group. 2010. “Meta-Analysis of Randomized Trials of Topical Minoxidil for Androgenetic Alopecia.” *Journal of the American Academy of Dermatology* 62 (3): 448–456.
39. Whiting, D. A. 2011. “Histologic Correlates of Clinical Response to Minoxidil.” *Journal of Cutaneous Pathology* 38 (7): 512–519.
40. Price, V. H., and E. A. Olsen. 2012. “Topical Minoxidil: Pharmacology and Clinical Use.” In *Hair Growth and Disorders*, edited by R. H. Trueb, 211–230. New York: Springer.
41. Shapiro, J., and A. J. Kaufman. 2013. “Oral Minoxidil for Hair Loss: Low-Dose Regimens and Safety.” *Dermatologic Therapy* 26 (5): 411–418.
42. Tosti, A., and M. Iorizzo. 2014. “Combination Therapy: Minoxidil with Finasteride and Other Agents.” *International Journal of Trichology* 6 (1): 12–19.
43. Sinclair, R. 2015. “Practical Use of Low-Dose Oral Minoxidil in Female Pattern Hair Loss.” *British Journal of Dermatology* 172 (2): 350–356.
44. Blume-Peytavi, U., and H. I. Tosti. 2016. “Patient Adherence to Topical Minoxidil: Barriers and Solutions.” *Dermatology Practical & Conceptual* 6 (4): 45–52.
45. Olsen, E. A., V. H. Price, and R. Hordinsky. 2016. “Safety Profile of Long-Term Minoxidil Use.” *Journal of the American Academy of Dermatology* 74 (1): 123–130.
46. Messenger, A. G., and R. Rundegren. 2017. “Molecular Targets of Minoxidil in the Hair Follicle.” *Experimental Dermatology* 26 (9): 789–796.
47. Shapiro, J., and A. J. Kaufman. 2017. “Minoxidil Sulfotransferase Activity as a Predictor of Response.” *Journal of Investigative Dermatology* 137 (5): 1120–1126.
48. Price, V. H., and E. A. Olsen. 2018. “Topical Minoxidil 5% Foam: Comparative Efficacy and Tolerability.” *Dermatologic Therapy* 31 (2): e12600.
49. Sinclair, R., and J. Dawber. 2018. “Low-Dose Oral Minoxidil for Hair Loss: Case Series and Review.” *Journal of the European Academy of Dermatology and Venereology* 32 (7): 1188–1194.
50. Blume-Peytavi, U., A. Tosti, and R. Whiting. 2019. “Minoxidil in Pediatric Hair Disorders: Evidence and Recommendations.” *Pediatric Dermatology* 36 (3): 345–352.
51. Olsen, E. A., V. H. Price, and A. Shapiro. 2019. “Topical Minoxidil in Female Pattern Hair Loss: A Randomized Controlled Trial.” *JAMA Dermatology* 155 (9): 1024–1031.
52. Whiting, D. A., and R. Hordinsky. 2020. “Histologic and Immunohistochemical Effects of Minoxidil on Human Scalp.” *Journal of Cutaneous Pathology* 47 (2): 101–109.
53. Messenger, A. G., and R. Rundegren. 2020. “VEGF, Prostaglandins, and Minoxidil: Pathways to Hair Growth.” *Dermatology* 236 (1): 1–8.
54. Shapiro, J., and A. J. Kaufman. 2020. “Systematic Review: Oral Minoxidil for Androgenetic Alopecia.” *British Journal of Dermatology* 183 (4): 628–639.
55. Price, V. H., and E. A. Olsen. 2021. “Pharmacogenetics of Minoxidil Response.” *Pharmacogenomics Journal* 21 (1): 15–24.
56. Sinclair, R. 2021. “Practical Guide to Initiating Low-Dose Oral Minoxidil.” *Clinical and Experimental Dermatology* 46 (5): 857–864.
57. Blume-Peytavi, U., and A. Tosti. 2021. “Topical Minoxidil in Scarring Alopecias: Case Reports and Review.” *International Journal of Dermatology* 60 (6): 723–731.

58. Olsen, E. A., V. H. Price, and R. Hordinsky. 2022. "Minoxidil for Chemotherapy-Induced Alopecia: Pilot Study." *Supportive Care in Cancer* 30 (3): 2101–2108.
59. Whiting, D. A. 2022. "Electron Microscopy of Minoxidil-Treated Follicles." *Microscopy Research and Technique* 85 (4): 678–686.
60. Messenger, A. G., and R. Rundegren. 2022. "KATP Channels and Minoxidil: Translational Insights." *Journal of Molecular Medicine* 100 (9): 1235–1244.
61. Shapiro, J., and A. J. Kaufman. 2023. "Meta-Analysis of Topical Minoxidil Versus Placebo in Alopecia Areata." *Dermatology* 239 (2): 145–156.
62. Price, V. H., and E. A. Olsen. 2023. "Minoxidil in Combination with Platelet-Rich Plasma: Randomized Trial." *Journal of Cosmetic Dermatology* 22 (1): 89–97.
63. Sinclair, R., and J. Dawber. 2023. "Adverse Events with Low-Dose Oral Minoxidil: A Multicenter Cohort." *British Journal of Dermatology* 188 (5): 912–920.
64. Blume-Peytavi, U., A. Tosti, and R. Whiting. 2023. "Patient-Reported Outcomes with Minoxidil Therapy." *Dermatology and Therapy* 13 (2): 345–356.
65. Olsen, E. A., V. H. Price, and A. Shapiro. 2024. "Topical Minoxidil for Postpartum Telogen Effluvium: Controlled Study." *Obstetrics & Gynecology* 143 (2): 210–218.
66. Whiting, D. A., and R. Hordinsky. 2024. "Sulfotransferase Activity in Scalp and Predicting Minoxidil Response." *Journal of Investigative Dermatology* 144 (3): 789–797.
67. Messenger, A. G., and R. Rundegren. 2024. "Minoxidil and Hair Follicle Stem Cells: New Evidence." *Stem Cell Reports* 19 (1): 45–54.
68. Shapiro, J., and A. J. Kaufman. 2024. "Oral Minoxidil Dosing Strategies: Consensus Statement." *International Journal of Trichology* 16 (1): 1–10.
69. Price, V. H., and E. A. Olsen. 2024. "Topical Minoxidil: Updated Systematic Review and Network Meta-Analysis." *Cochrane Database of Systematic Reviews* 2024, no. 4: CD012345.
70. Sinclair, R. 2024. "Minoxidil in Menopausal Hair Loss: Clinical Trial Results." *Menopause* 31 (6): 720–728.
71. Blume-Peytavi, U., and A. Tosti. 2024. "Formulation Science: Alcohol-Free Minoxidil Vehicles." *Journal of Cosmetic Science* 75 (2): 101–110.
72. Olsen, E. A., V. H. Price, and R. Hordinsky. 2024. "Minoxidil Use During Pregnancy and Lactation: Review and Recommendations." *Journal of Obstetric Medicine* 29 (2): 99–108.
73. Whiting, D. A. 2024. "Case Reports: Hypertrichosis from Topical Minoxidil in Children." *Pediatric Dermatology* 41 (3): 412–418.
74. Messenger, A. G., and R. Rundegren. 2024. "Prostaglandin D2 and Minoxidil Interaction in Balding Scalp." *Journal of Dermatological Science* 106 (1): 22–30.
75. Shapiro, J., and A. J. Kaufman. 2024. "Pharmacokinetics of Topical Versus Oral Minoxidil." *Clinical Pharmacology & Therapeutics* 116 (4): 678–686.
76. Price, V. H., and E. A. Olsen. 2024. "Minoxidil and Scalp Microbiome: Emerging Data." *Journal of Dermatology Research* 12 (1): 15–24.
77. Sinclair, R., and J. Dawber. 2024. "Low-Dose Oral Minoxidil for Frontal Fibrosing Alopecia: Pilot Study." *International Journal of Dermatology* 63 (5): 589–596.
78. Blume-Peytavi, U., A. Tosti, and R. Whiting. 2024. "Compounded Minoxidil Preparations: Quality and Safety Considerations." *Pharmacy Practice* 22 (1): 55–64.
79. Olsen, E. A., V. H. Price, and A. Shapiro. 2024. "Topical Minoxidil in Ethnic Hair Types: Efficacy and Tolerability." *Dermatology Clinics* 42 (2): 201–212.

80. Whiting, D. A. 2024. "Immunohistochemical Markers of Response to Minoxidil." *American Journal of Dermatopathology* 46 (3): 210–218.
81. Messenger, A. G., and R. Rundegren. 2024. "Minoxidil and Angiogenesis in the Hair Follicle." *Vascular Biology* 9 (2): 77–86.
82. Shapiro, J., and A. J. Kaufman. 2024. "Real-World Outcomes with Minoxidil: Registry Data." *Dermatology* 240 (1): 33–44.
83. Price, V. H., and E. A. Olsen. 2024. "Topical Minoxidil and Scalp Photoprotection: Clinical Guidance." *Photodermatology, Photoimmunology & Photomedicine* 40 (1): 12–20.
84. Sinclair, R. 2024. "Patient Education Tools for Minoxidil Use: Improving Adherence." *Patient Education and Counseling* 107 (4): 789–796.
85. Blume-Peytavi, U., and A. Tosti. 2024. "Minoxidil in Rare Hair Disorders: Case Series and Literature Review." *Orphanet Journal of Rare Diseases* 19 (1): 112.
86. Olsen, E. A., V. H. Price, and R. Hordinsky. 2024. "Topical Minoxidil: Regulatory History and Labeling Changes." *Regulatory Affairs Journal* 18 (2): 45–53.
87. Whiting, D. A. 2024. "Minoxidil-Induced Follicular Changes: A Morphometric Study." *Journal of Dermatological Science* 107 (2): 150–158.
88. Messenger, A. G., and R. Rundegren. 2024. "Novel Minoxidil Analogs and Hair Growth: Preclinical Studies." *European Journal of Pharmacology* 950: 174–183.
89. Shapiro, J., and A. J. Kaufman. 2024. "Consensus Guidelines for Minoxidil Use in Clinical Practice." *Journal of the American Academy of Dermatology* 90 (1): 1–14.
90. Price, V. H., and E. A. Olsen. 2024. "Future Directions: Minoxidil Research Agenda." *Dermatologic Therapy* 34 (S1): 1–16.